Minimally symptomatic, metastatic hormone-refractory Prostate cancer
Drug | Drug Name | Drug Description |
---|---|---|
DB06688 | Sipuleucel-T | An autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB06688 | Sipuleucel-T | Prostatic acid phosphatase | target |
Drug | Drug Name | Phase | Status | Count |
---|